

FEB. 7. 2002 12:40PM

LADAS & PARRY CHICAGO OFFICE

NO. 9236 P. 1

LAW OFFICES

LADAS & PARRY

1/14
JC10 Rec'd PGT/PTO 07 FEB 2002

224 South Michigan Avenue • Chicago, Illinois 60604, U.S.A.

Telephone: (312) 427-1300

Telefax: (312) 427-6663 (312) 427-6668

TECH CENTER 600/690

MAR 08 2002

RECEIVED

1600

THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY WHICH IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE. If the reader of this message is the intended recipient or an employee or agent responsible for delivering the message to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by telephone and return the original message to us by mail. Thank you.

LENGTH OF TRANSMISSION (INCLUSIVE OF THIS SHEET): 4 page(s)

DATE: February 7, 2002

FROM: Richard J. Streit/ds

TO: Commissioner for Patents
Washington, D.C. 20231

Fax No. 703-308-7751

RE: John P. McKearn et al
U.S. Serial No. 09/857,873
Filed October 5, 2001
METHOD OF USING CYCLOOXYGENASE-2 INHIBITOR
AND ONE OR MORE ANTINEOPLASTIC AGENTS AS A
COMBINATION THERAPY IN THE TREATMENT OF
NEOPLASIA
Docket: CU-2559

REMARKS:

Attached is a Request for Corrected Filing Receipt

DOCKET: CU-2559

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: John P. McKEARN et al)
SERIAL NO: 09/857,873) Group Art Unit:
FILING DATE: October 5, 2001) 1614
TITLE: METHOD OF USING CYCLOOXYGENASE-2 INHIBITOR)
AND ONE OR MORE ANTINEOPLASTIC AGENTS AS)
A COMBINATION THERAPY IN THE TREATMENT)
OF NEOPLASIA)

The Commissioner for Patents
Washington, D.C. 20231

REQUEST FOR CORRECTED FILING RECEIPT

Dear Sir:

The official filing receipt has been received from the Patent Office in the above application.


There are several errors therein as shown on the attached copy, and as follows:

1. The state of residence of three inventors (John P. McKearn; Alane T. Koki and Jaime L. Masferrer) are incorrect as the state of residence should be Missouri (MO).
2. The word "cyclooxygenase" has been misspelled in the title.
3. The title is incomplete - after "in the treatment", "of neoplasia" should be included.

Reference is made to the Combined Declaration & Power of Attorney which was filed on October 5, 2001.

It is believed that no fee is due since the correction is not due to any error by the applicant and issuance of a corrected filing receipt is respectfully requested.

Respectfully submitted,


Attorney for Applicant

February 7, 2002
Date

/6

Richard J. Street, Reg. 25765
c/o Ladas & Parry
224 South Michigan Avenue
Chicago, Illinois 60604
(312) 427-1300

RECEIVED

MAR 08 2002



UNITED STATES PATENT AND TRADEMARK OFFICE

 TECH CENTER
 COMMISSIONER OF PATENTS AND TRADEMARKS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20231
 www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY. DOCKET NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/857,873	10/05/2001	1614	2484	CU-2559 RJS		103	3

CONFIRMATION NO. 2817

FILING RECEIPT



OC000000006932757

Ladas & Parry
 Suite 1200
 224 South Michigan Avenue
 Chicago, IL 60604

Date Mailed: 10/22/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

MO (MISSOURI)

John P. McKearn, Glencoe, ~~MT~~;
 Gary Gordon, Highland, IL;
 James J. Cunningham, Chicago, IL;
 Stephen T. Gately, Palatine, IL;
 Alane T. Koki, Beaufort, ~~MT~~, MO
 Jaime L. Masferrer, Ballwin, ~~MT~~; MO

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/US99/30693 12/22/1999
 WHICH CLAIMS BENEFIT OF 60/113,786 12/23/1998

Foreign Applications

Projected Publication Date: Not Applicable, filed prior to November 29, 2000

Non-Publication Request: No

Early Publication Request: No

Title

CYCLOOXYGENASE

Method of using a cyclooxygenase 2 inhibitor and one or more antineoplastic agents as a

combination therapy in the treatment OF NEOPLASIA

Preliminary Class

514

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).